Avaliação do site drug-dev.com
Drug Development & Delivery - The Latest Methods in Drug Development
Gerado a 15 de Março de 2026 09:34 AM
Estatísticas desatualizadas? ATUALIZE !
O resultado é de 64/100
Conteúdo SEO
Título
Drug Development & Delivery - The Latest Methods in Drug Development
Cumprimento : 68
Perfeito, o Título contém entre 10 e 70 caracteres.
Descrição
Drug Development & Delivery is a print and online publisher that presents the latest scientific methods in drug development for professionals.
Cumprimento : 142
Perfeito, a Descrição META contém entre 70 e 160 caracteres.
Palavras-chave
Mau. Não detetámos palavras-chave META na sua página.
Propriedades Og Meta
Boa! Esta página tira vantagens das propriedades Og.
| Propriedade | Conteúdo |
|---|---|
| locale | en_US |
| type | website |
| title | Drug Development & Delivery - The latest scientific methods in drug development |
| description | Drug Development & Delivery is a print and online content provider that presents the latest scientific methods in drug development for professionals in R&D, APIs, pre-formulation, formulation development and analytical methods. |
| url | https://drug-dev.com/ |
| site_name | Drug Development and Delivery |
| image | https://drug-dev.com/wp-content/uploads/2018/06/Drug-Dev-Homepage.jpg |
| image:width | 2048 |
| image:height | 1062 |
| image:type | image/jpeg |
Cabeçalhos
| H1 | H2 | H3 | H4 | H5 | H6 |
| 1 | 4 | 52 | 6 | 1 | 0 |
- [H1] Don’t miss out on this exclusive content!
- [H2] EXPERT CONTENT & RESOURCES
- [H2] EXCLUSIVE WHITEPAPERS
- [H2] EXCLUSIVE WEBINARS
- [H2] MARKET NEWS & TRENDS
- [H3] SPECIAL FEATURE - Artificial Intelligence in Drug Discovery, Development & Delivery
- [H3] FORMULATION FORUM - Solid Oral Dosages: Controlled Release of Drugs
- [H3] LEADERSHIP PANEL - Trends to Watch for in 2026
- [H3] PREFILLABLE SYRINGE SYSTEM - Beyond Components: Designing Prefillable Syringe Systems to Streamline Success
- [H3] CONTROLLED RELEASE - Challenges in Consistent & Predictable Delivery of Drugs Using Oral Controlled Release Technologies
- [H3] EXECUTIVE INTERVIEW - Incannex Healthcare: Pioneering the Future of Cannabinoid & Psychedelic Therapies
- [H3] CELL & GENE THERAPY - What the Industry Can Learn From Baby KJ About Optimizing CRISPR Development
- [H3] PLATFORM TECHNOLOGY - How PolyPid’s PLEX Unlocks the Potential of Local & Prolonged Release
- [H3] MAB FORMULATION & FILL-FINISH - Obstacles in Monoclonal Antibody Formulation & Fill-Finish
- [H3] EXECUTIVE INTERVIEW - CERo Therapeutics: A Novel Approach to Treating Cancer
- [H3] MRNA THERAPEUTICS - Strategies for Enhanced Stability, Targeted Delivery & Safe Translation
- [H3] 2026 COMPANY PROFILES & CAPABILITIES
- [H3] PURIFICATION STRATEGIES - Purification at Scale: Overcoming Chromatography Challenges for Advanced Modalities
- [H3] DRUG DEVELOPMENT - Common CMC Pitfalls in Orphan Drug Development
- [H3] 3D PRINTING - The Future of 3D Printing in Pharma: Aprecia’s Vision for Transformative Medicine
- [H3] Biocatalysis Without Barriers for Efficient Small Molecule Process Development
- [H3] VIDEO - Built for the Clinic: Smart Drug Product Design for Accelerated Clinical Development
- [H3] Atossa Therapeutics: Unlocking the Platform Potential of (Z)-Endoxifen Across Oncology & Rare Disease
- [H3] Drug Combination Screening in Oncology: Advancing Predictive Strategies for Precision Drug Development
- [H3] How Can a Stage-Based Program to Determine HME Applicability Benefit Your API?
- [H3] WHITE PAPER - Stop Guessing. Start Predicting: Rethinking Early Oral Drug Development
- [H3] WHITE PAPER - Small Molecules: Choosing the Right Development Path
- [H3] WHITE PAPER - How Advanced Containment Technology Is Reshaping High-Potency API Micronization
- [H3] WHITE PAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations
- [H3] WHITE PAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers
- [H3] ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules
- [H3] WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future
- [H3] WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing
- [H3] WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development
- [H3] WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations
- [H3] Vetter Des Plaines Facility is the German American Chamber of Commerce’s Investment of the Year
- [H3] Neuland to Open Commercial Peptide Facility as part of Planned Phased Expansion
- [H3] Lonza & Genetix Biotherapeutics Extend Commercial Manufacturing Agreement for ZYNTEGLO
- [H3] Centauri Therapeutics Granted FDA QIDP Status for CTX-187 Treatment of Gram-Negative Bacterial Infections
- [H3] Upperton Submits MHRA License Application for Annex 1 Sterile Manufacturing Facility Following APS Validation
- [H3] Biologos Appoints New CEO, Celebrates 50 Years of Growth & Innovation
- [H3] Medicus Pharma Reports Positive Phase 2 Topline Data Observing 73% Clinical Clearance & 40% Histological Clearance
- [H3] LabVantage Solutions Introduces LabVantage CORTEX, Advancing its LIMS Platform for AI-Driven Laboratory Operations
- [H3] Codexis Signs Agreement to Manufacture 50 g siRNA Using its ECO Synthesis Manufacturing Platform
- [H3] FUJIFILM Biotechnologies Unveils ShunzymeX Precision Purification Technology
- [H3] BioDuro & Cenra Launch Joint Venture to Expand Resilient Global API Manufacturing Capacity
- [H3] NorthSea Therapeutics Announces Achievement of Key Regulatory Milestones for Orziloben
- [H3] ESTEVE CDMO Commences $15.5 Million Expansion of Chicago Small Molecule API Facility
- [H3] Bioxytran Reports Positive Study Results for a Broad-Range Antiviral Drug in Mild-to-Moderate COVID-19
- [H3] Quotient Sciences Extends Commercial Manufacturing Partnership for Ultra-Rare Disease Treatment
- [H3] Neurizon Initiates Dosing of NUZ-001 in HEALEY ALS Platform Trial
- [H3] MGS Acquires European-Based Medical Injection Molder Knudsen Plast A/S
- [H3] TARA-002 Demonstrates 68% Complete Response Rate at 6 Months in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- [H3] etherna´s Intratumoral mRNA/LNP Platform Advances to Clinical Testing in Nonmelanoma Skin Cancer Led by Almirall
- [H3] SolasCure Completes Phase 2 Clinical Trial Demonstrating Accelerated Healing With Aurase Wound Gel
- [H3] MARKET SEGMENTS
- [H3] CORPORATE
- [H4] VIDEO SPOTLIGHT
- [H4] COMPANY PROFILES
- [H4] TECHNOLOGY & SERVICES SHOWCASE
- [H4] eBOOKS
- [H4] AUDIO SPOTLIGHT
- [H4] INDUSTRY EVENTS
- [H5] Sign Up for a free Subscription
Imagens
Encontrámos 46 imagens nesta página.
43 atributos ALT estão vazios ou em falta. É recomendado adicionar texto alternativo de modo a que os motores de busca identifiquem melhor o conteúdo das suas imagens.
Rácio Texto/HTML
Rácio : 31%
Ideal! O rácio de texto para código HTML desta página está entre 25 e 70 porcento.
Flash
Perfeito, não foi encontrado conteúdo Flash nesta página.
Iframe
Oh, não, esta página tem Iframes na página, o que significa que o conteúdo destas não pode ser indexado.
Ligações SEO
Reescrita de URL
Perfeito. As ligações aparentam ser limpas!
Underscores (traços inferiores) nas URLs
Perfeito. Não foram encontrados 'underscores' (traços inferiores) nas suas URLs.
Ligações para a própria página
Encontrámos um total de 156 ligações incluindo 0 ligações a ficheiros
Palavras-chave SEO
Núvem de palavras-chave
solubility pharma recently manufacturing delivery development announced clinical formulation drug
Consistência das Palavras-chave
| Palavra-chave | Conteúdo | Título | Palavras-chave | Descrição | Cabeçalhos |
|---|---|---|---|---|---|
| drug | 38 |  |
 |
|
|
| development | 28 | |
|
|
|
| delivery | 20 | |
|
|
|
| pharma | 16 | |
|
|
|
| recently | 15 | |
|
|
|
Usabilidade
Url
Domínio : drug-dev.com
Cumprimento : 12
Favicon
Ótimo, o site tem um favicon.
Facilidade de Impressão
Não encontrámos CSS apropriado para impressão.
Língua
Otimo! A língua declarada deste site é en.
Dublin Core
Esta página não tira vantagens do Dublin Core.
Documento
Tipo de Documento
HTML 5
Codificação
Perfeito. O conjunto de caracteres UTF-8 está declarado.
Validação W3C
Erros : 0
Avisos : 0
Privacidade do Email
Boa! Nenhum endereço de email está declarado sob a forma de texto!
HTML obsoleto
Fantástico! Não detetámos etiquetas HTML obsoletas.
Dicas de Velocidade
|
Excelente, este site não usa tablelas dentro de tabelas. |
|
Oh não, o site usa estilos CSS nas etiquetas HTML. |
|
Oh, não! O site utiliza demasiados ficheiros CSS (mais que 4). |
|
Oh, não! O site utiliza demasiados ficheiros JavaScript (mais que 6). |
|
Perfeito, o site tira vantagens da compressão gzip. |
Dispositivos Móveis
Otimização para dispositivos móveis
|
Icon Apple |
|
Meta Viewport Tag |
|
Conteúdo Flash |
Otimização
XML Sitemap
Perfeito, o site tem um mapa XML do site (sitemap).
| https://drug-dev.com/sitemap_index.xml |
Robots.txt
https://drug-dev.com/robots.txt
Perfeito, o seu site tem um ficheiro robots.txt.
Analytics
Perfeito, o site tem uma ferramenta analítica para a análise de atividade.
Google Analytics |
PageSpeed Insights
Dispositivo
Categorias
Free SEO Testing Tool
Free SEO Testing Tool é uma ferramenta gratuita que o ajuda a avaliar o seu site